dc.contributor.author | Soofiyani, SR | |
dc.contributor.author | Baradaran, B | |
dc.contributor.author | Lotfipour, F | |
dc.contributor.author | Kazemi, T | |
dc.contributor.author | Mohammadnejad, L | |
dc.date.accessioned | 2018-08-26T08:56:07Z | |
dc.date.available | 2018-08-26T08:56:07Z | |
dc.date.issued | 2013 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54398 | |
dc.description.abstract | Gene therapy is one of the most attractive fields in medicine. The concept of gene delivery to tissues for clinical applications has been discussed around half a century, but scientist's ability to manipulate genetic material via recombinant DNA technology made this purpose to reality. Various approaches, such as viral and non-viral vectors and physical methods, have been developed to make gene delivery safer and more efficient. While gene therapy initially conceived as a way to treat life-threatening disorders (inborn errors, cancers) refractory to conventional treatment, to date gene therapy is considered for many non-life-threatening conditions including those adversely influence on a patient's quality of life. Gene therapy has made significant progress, including tangible success, although much slower than was initially predicted. Although, gene therapies still at a fairly primitive stage, it is firmly science based. There is justifiable hope that with enhanced pathobiological understanding and biotechnological improvements, gene therapy will be a standard part of clinical practice within 20 years. é 2013 by Tabriz University of Medical Sciences. | |
dc.language.iso | English | |
dc.relation.ispartof | Advanced Pharmaceutical Bulletin | |
dc.subject | adenovirus vector | |
dc.subject | interleukin 2 receptor gamma | |
dc.subject | lentivirus vector | |
dc.subject | parvovirus vector | |
dc.subject | retrovirus vector | |
dc.subject | article | |
dc.subject | clinical trial (topic) | |
dc.subject | electroporation | |
dc.subject | ex vivo gene transfer | |
dc.subject | gene gun immunization | |
dc.subject | gene therapy | |
dc.subject | gene vector | |
dc.subject | germ line gene therapy | |
dc.subject | human | |
dc.subject | hydrodynamics | |
dc.subject | immune response | |
dc.subject | in vivo gene transfer | |
dc.subject | interleukin 2 receptor gamma gene | |
dc.subject | nonhuman | |
dc.subject | nonviral gene delivery system | |
dc.subject | severe combined immunodeficiency | |
dc.subject | somatic gene therapy | |
dc.subject | ultrasound | |
dc.subject | viral gene delivery system | |
dc.subject | viral gene therapy | |
dc.title | Gene therapy, early promises, subsequent problems, and recent breakthroughs | |
dc.type | Article | |
dc.citation.volume | 3 | |
dc.citation.issue | 2 | |
dc.citation.spage | 249 | |
dc.citation.epage | 255 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.5681/apb.2013.041 | |